|
Q4 2021
|
144 |
168,461 |
AAPL, MDB, ADYEN.AS, RLAY
|
13F-HR
|
2/2/2022 |
000144164622000001 |
|
Q3 2021
|
162 |
162,585 |
ADYEN.AS, AAPL, MDB, RLAY
|
13F-HR
|
11/8/2021 |
000144164621000008 |
|
Q2 2021
|
158 |
149,325 |
RLAY, AAPL, TPL, ADYEN.AS
|
13F-HR
|
8/11/2021 |
000144164621000007 |
|
Q1 2021
|
208 |
157,224 |
TPL, RLAY, AAPL, GLOBAL BLOOD THERAPEUTICS INC COM
|
13F-HR
|
5/6/2021 |
000144164621000004 |
|
Q4 2020
|
257 |
158,311 |
AAPL, RLAY, GLOBAL BLOOD THERAPEUTICS INC COM, BBIO
|
13F-HR
|
2/10/2021 |
000144164621000002 |
|
Q3 2020
|
240 |
128,968 |
RLAY, GLOBAL BLOOD THERAPEUTICS INC COM, AAPL, SAFT
|
13F-HR
|
11/12/2020 |
000144164620000014 |
|
Q2 2020
|
216 |
116,465 |
GLOBAL BLOOD THERAPEUTICS INC COM, SAFT, AMZN, ADYEN.AS
|
13F-HR
|
8/13/2020 |
000144164620000012 |
|
Q1 2020
|
183 |
101,721 |
GLOBAL BLOOD THERAPEUTICS INC COM, SAFT, SPY, AMZN
|
13F-HR
|
5/12/2020 |
000144164620000010 |
|
Q4 2019
|
201 |
122,633 |
GLOBAL BLOOD THERAPEUTICS INC COM, SAFT, PTLA, MYOK
|
13F-HR
|
2/13/2020 |
000144164620000007 |
|
Q3 2019
|
144 |
98,991 |
GLOBAL BLOOD THERAPEUTICS INC, PTLA, MYOK, IVV
|
13F-HR
|
11/15/2019 |
000144164619000004 |
|
Q2 2019
|
191 |
209,637 |
GLOBAL BLOOD THERAPEUTICS INC, PTLA, AAPL, MSFT
|
13F-HR
|
8/14/2019 |
000144164619000003 |
|
Q1 2019
|
213 |
256,213 |
GLOBAL BLOOD THERAPEUTICS INC, PTLA, AAPL, MSFT
|
13F-HR
|
5/15/2019 |
000144164619000002 |
|
Q4 2018
|
226 |
215,403 |
MSFT, PFE, MYOK, PTLA
|
13F-HR
|
2/15/2019 |
000144164619000001 |
|
Q3 2018
|
221 |
255,582 |
GLOBAL BLOOD THERAPEUTICS, AAPL, MSFT, MYOK
|
RESTATEMENT
|
11/14/2018 |
000144164618000007 |
|
Q2 2018
|
235 |
261,827 |
GLOBAL BLOOD THERAPEUTICS, MYOK, AAPL, MSFT
|
13F-HR
|
8/15/2018 |
000144164618000004 |
|
Q1 2018
|
88 |
187,666 |
BAC, JPM, MSFT, AAPL
|
RESTATEMENT
|
9/5/2018 |
000144164618000005 |
|
Q4 2017
|
80 |
284,113 |
MSFT, AAPL, JPM, BAC
|
13F-HR
|
2/12/2018 |
000144164618000001 |
|
Q3 2017
|
87 |
275,338 |
AAPL, MSFT, JPM, CHKP
|
13F-HR
|
11/13/2017 |
000144164617000004 |
|
Q2 2017
|
94 |
250,098 |
AAPL, MSFT, EPD, JPM
|
13F-HR
|
8/11/2017 |
000144164617000003 |
|
Q1 2017
|
89 |
243,194 |
AAPL, MSFT, TCP, EPD
|
13F-HR
|
5/2/2017 |
000144164617000002 |
|
Q4 2016
|
78 |
220,363 |
MSFT, EPD, TCP, JPM
|
13F-HR
|
1/17/2017 |
000144164617000001 |
|
Q3 2016
|
77 |
228,842 |
EPD, BGS, MSFT, HP
|
13F-HR
|
10/4/2016 |
000144164616000011 |
|
Q2 2016
|
75 |
238,339 |
EPD, SPH, APU, HP
|
13F-HR
|
7/8/2016 |
000144164616000010 |
|
Q1 2016
|
83 |
222,953 |
OMC, APU, FISV, MCHP
|
13F-HR
|
4/7/2016 |
000144164616000009 |
|
Q4 2015
|
89 |
212,188 |
OMC, MCHP, FISV, AAPL
|
13F-HR
|
2/11/2016 |
000144164616000008 |
|
Q3 2015
|
107 |
242,744 |
OMC, GSK, AAPL, AVY
|
13F-HR
|
11/10/2015 |
000144164615000007 |
|
Q2 2015
|
107 |
242,744 |
OMC, GSK, AAPL, AVY
|
13F-HR
|
8/10/2015 |
000144164615000006 |
|
Q1 2015
|
98 |
445,004 |
AAPL, MCHP, OMC, GSK
|
13F-HR
|
5/11/2015 |
000144164615000005 |
|
Q4 2014
|
97 |
415,677 |
KMI, TCP, NVS, FISV
|
RESTATEMENT
|
2/18/2015 |
000144164615000004 |
|
Q3 2014
|
94 |
352,052 |
TCP, EPD, NVS, BPL
|
13F-HR
|
10/15/2014 |
000144164614000004 |
|
Q2 2014
|
98 |
363,566 |
EPD, BPL, GIS, OKS
|
13F-HR
|
7/30/2014 |
000144164614000003 |
|
Q1 2014
|
81 |
95,343 |
ADP, FISV, BCR, PB
|
13F-HR
|
4/29/2014 |
000144164614000002 |
|
Q4 2013
|
80 |
86,540 |
ADP, FISV, PH, PB
|
13F-HR
|
1/21/2014 |
000144164614000001 |